Affordable Access

Iatrogenic myelomonocytic leukemia following melphalan treatment of scleromyxedema.

Authors
Type
Published Article
Journal
Cutis
Publication Date
Volume
39
Issue
3
Pages
219–223
Identifiers
PMID: 3470169
Source
Medline
License
Unknown

Abstract

We report the case of a patient with scleromyxedema with abnormal monoclonal gamma globulin of the kappa type who was treated with melphalan (Alkeran), an alkylating agent. After nine and one-half years of therapy, the patient showed myelomonocytic leukemia. The risk of secondary malignancies must be considered when weighting the benefits and risks of melphalan treatment.

Statistics

Seen <100 times